Intercept appoints Jared M. Freedberg as general counsel
Intercept Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced the appointment of Jared Freedberg as General Counsel and Secretary. He joins Intercept from Immunomedics, which was acquired by Gilead Sciences in October of 2020.
Mr. Freedberg was previously General Counsel and Secretary and a member of the Executive Leadership Team for Immunomedics, with responsibility for management of all legal activities, including compliance, securities, corporate and board governance, contracting, IP strategy and management, business development and litigation management.
Prior to joining Immunomedics, Mr. Freedberg served as General Counsel, Specialty Generics Operating Division, and Vice President, Business Development and Licensing at Mallinckrodt Pharmaceuticals. From 2001-2016, he held positions of increasing responsibility at Covance and was a member of Covance’s Global Executive Leadership Team as Head of Strategy and Business Development from 2014-2016, during which time he led the global integration of LabCorp’s $6 billion acquisition of Covance.
“His substantial legal and business development expertise will be invaluable as we focus on enhancing the growth of our foundational PBC business, supporting our NASH regulatory process in the United States and Europe, and building our pipeline” said Jerry Durso, President and Chief Executive Officer of Intercept. “I am thrilled to be joining Intercept because of the company’s unique focus on helping patients with challenging liver diseases that have limited or no treatment options,” said Mr. Freedberg. “We have a tremendous opportunity to build on the company’s strong foundation in 2021 and I look forward to being part of a team that will help shape the future of Intercept.”